2023-06-27 18:51:07
The professional medicine union (Leem) presented on Tuesday, June 27 the rather alarming results of its study on access to the French medicine market and the attractiveness of the country at European level. This report, conducted by the strategy consulting firm Roland Berger, aims to measure « the loss of opportunity for French patients, given the delays in access”et “the impact of this dissonance of public policies on the attractiveness of France”.
In terms of access to medicines, “France is far from being a European leader, as the government wishes”, underlines Christophe Durand, president of the Leem access commission, in reference to the objectives set in 2021 by Emmanuel Macron as part of the 2030 health innovation plan. The figures speak for themselves. A third of medicines that received European marketing authorization between 2018 and 2021 were not available to French patients at the end of 2022, compared to 13% in Germany. Access hampered by price negotiation difficulties.
“Complexity of regulation”
Another problematic point, according to Leem: “The delays in accessing medicines for patients exceed the European regulatory delays”, due to long evaluation times, mission entrusted to the High Authority for Health (HAS). On average, French patients have to wait 380 days longer than the Germans, 179 days longer than the English, but 121 days shorter than the Spaniards.
While pharmaceutical laboratories increase their investments in research and development in Europe, France remains stable. In question, clinical research in decline against Spain, which has conducted a “offensive program” these last years. Among the 3,019 industrial clinical trials on drugs launched in 2021, France participated in 13% of them, compared to 16% in Spain.
According to manufacturers, the “complexity of regulation is the main obstacle to investment in research and development”. The Leem points to the need to “simplify” THE ” methods “ of the HAS. Christophe Durand wonders: “Why reassess the benefits and risks of the drug when they have already been assessed by the European Commission? »
#France #poor #European #student #access #medicines